API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/12/08/2793183/0/en/eFFECTOR-Therapeutics-Announces-New-Positive-Interim-Data-from-Dose-Escalation-and-Phase-2-Expansion-Cohorts-of-Zotatifin-in-ER-Metastatic-Breast-Cancer-Patients.html
https://www.globenewswire.com//news-release/2023/11/28/2786889/0/en/eFFECTOR-Receives-U-S-FDA-Fast-Track-Designation-for-Zotatifin-in-Combination-with-Fulvestrant-and-Abemaciclib-for-Treatment-of-ER-HER2-Advanced-Metastatic-Breast-Cancer.html
https://www.globenewswire.com//news-release/2023/11/15/2780970/0/en/eFFECTOR-to-Present-New-Clinical-Data-from-Dose-Escalation-and-Phase-2-Expansion-Cohorts-of-Zotatifin-in-Patients-with-ER-Metastatic-Breast-Cancer-at-SABCS-2023-Annual-Meeting.html
https://www.clinicaltrialsarena.com/news/effector-data-trial-zotatifin-covid-19/
https://www.globenewswire.com/news-release/2023/02/21/2612164/0/en/eFFECTOR-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-1b-Clinical-Trial-of-Zotatifin-for-the-Treatment-of-COVID.html
https://www.globenewswire.com//news-release/2023/01/05/2584087/0/en/eFFECTOR-Therapeutics-Provides-Positive-Clinical-Data-Update-for-Zotatifin-and-General-Corporate-Update.html
https://www.globenewswire.com/news-release/2022/09/14/2515881/0/en/eFFECTOR-Therapeutics-Doses-First-Patient-in-Second-Cohort-of-Phase-1b-Clinical-Trial-of-Zotatifin-for-the-Treatment-of-COVID-19.html
https://www.globenewswire.com/news-release/2022/06/05/2456359/0/en/eFFECTOR-Therapeutics-Reports-Positive-Interim-Results-in-Zotatifin-eFT226-Phase-1-2-Clinical-Trial-at-ASCO-2022-Showing-Safety-and-Tolerability-and-Initial-Signals-of-Clinical-Act.html
https://www.globenewswire.com/news-release/2022/05/26/2451682/0/en/eFFECTOR-Therapeutics-to-Present-Interim-Data-from-Ongoing-Zotatifin-Phase-1-2-Dose-Escalation-and-Expansion-Trial-at-2022-ASCO-Annual-Meeting.html
https://www.sciencealert.com/there-are-nearly-50-already-approved-drugs-that-could-help-us-fight-covid-19